• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24941 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Microinvasive surgical (MIGS) devices and procedures for the treatment of moderate to severe glaucoma]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Xeljanz (Juvenile Idiopathic Arthritis - JIA)]
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of teledermatology to support the management of primary care referrals
2025     Austrian Institute for Health Technology Assessment (AIHTA) Trauma care: teaching recovery technique (TRT) to children and adolescent refugees. Systematic review and evaluation of Austrian TRT-Programme at AFYA
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Blincyto ( B-lineage acute lymphoblastic leukemia)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enspryng (neuromyelitis optica spectrum disorder- NMOSD)]
2025     National Institute for Health and Care Excellence (NICE) Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment. NICE HealthTech guidance 756
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enstilar (Psoriasis vulgaris)]
2025     National Institute for Health and Care Excellence (NICE) Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment. NICE HealthTech guidance 748
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Sotender application for allocating social services and health care gig work
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Fespixon cream (Diabetic foot ulcers- DFUs)]
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment. NICE HealthTech guidance 746
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Zoturi — Online Story-Based Support for youth and families
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Kepida (breast cancer)]
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for soft tissue procedures: early value assessment. NICE HealthTech guidance 742
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Orla INR Remote Monitoring
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Onivyde (Advanced pancreatic cancer- first line treatment)]
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for orthopaedic procedures: early value assessment. NICE HealthTech guidance 743
2025     Norwegian Medical Products Agency (NOMA) [A leadless pacemaker, MicraTM Transcatheter Pacing System, in (sub-groups of) patients with indication for single-chamber ventricular pacing: a single technology re-assessment]
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Suvanto Care Safety Service
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Peyona (Apnea of prematurity - AOP)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2025     Norwegian Medical Products Agency (NOMA) [Magnetic resonance guided high-intensity focused ultrasound for treatment of essential tremor: single technology assessment]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vitrakvi (NTRK gene fusions in solid tumors)]
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment. NICE HealthTech guidance 739
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for odronextamab (DLBCL) - First addendum to Project A24-18]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Omjjara (myelofibrosis - MF)]
2025     Norwegian Medical Products Agency (NOMA) [Tumor-treating fields (Optune) for treatment of glioblastoma: a rapid health technology assessment with submitted documentation]
2025     NIHR Health Technology Assessment programme A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – loncastuximab (DLBCL)]
2025     Norwegian Medical Products Agency (NOMA) [Volatile gas capture technology. Summary of a health technology assessment by Scottish Health Technologies Group: health technology assessment without submitted documentation]
2025     NIHR Health Technology Assessment programme Public and patient involvement (PPI) in the design, execution and dissemination of a trial: the BISTRO trial
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – epcoritamab (DLBCL)]
2025     NIHR Health Services and Delivery Research programme Development and implementation of a digital health intervention in routine care for long COVID patients: a comprehensive synopsis
2025     Agency for Care Effectiveness (ACE) Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
2025     Norwegian Medical Products Agency (NOMA) [Photon-counting detector computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer, pMMR) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: The PEACH mixed methods study
2025     Agency for Care Effectiveness (ACE) Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2025     Agency for Care Effectiveness (ACE) Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
2025     Norwegian Medical Products Agency (NOMA) Continuous and flash glucose monitoring in patients with type 2 diabetes treated with insulin
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirtobrutinib (CLL) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Treatment effect modifiers of cognitive behaviour therapy in people with psychosis: an individual participant data meta-analysis of RCTs
2025     Agency for Care Effectiveness (ACE) Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eplontersen (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code]
2025     NIHR Health Technology Assessment programme Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: CONFORM-OH pilot RCT and economic evaluation
2025     Agency for Care Effectiveness (ACE) Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: the UK Mini Mitral multicentre RCT
2025     Agency for Care Effectiveness (ACE) Onasemnogene abeparvovec for treating spinal muscular atrophy
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study
2025     Agency for Care Effectiveness (ACE) Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
2025     Swiss Federal Office of Public Health (FOPH) Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson’s disease: the ADepT-PD RCT pilot
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Evidence of the impact on and views of NHS staff following a colleague’s suicide to inform postvention guidance: a multi-methods study
2025     Agency for Care Effectiveness (ACE) Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Agency for Care Effectiveness (ACE) Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Haute Autorite de sante (HAS) [Next generation sequencing gene panel using circulating tumor DNA for medical lung cancer care]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis IVA) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [External beam radiotherapy delivered by ultra-hypofractionation for the treatment of prostate cancer]
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2024     HTA Region Stockholm [Effectiveness of intravesical instillation for overactive bladder including bladder pain syndrome]
2024     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1006
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Vosoritide in achondroplasia]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (ESCC - first-line treatment)
2024     HTA Region Stockholm [Comparing coronary computed tomography angiography (CCTA) to exercise electrocardiogram for suspected coronary artery disease: impact on patient outcomes]
2024     National Institute for Health and Care Excellence (NICE) Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over. NICE technology appraisal guidance 1002
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evaluation of the lung cancer screening pilot project - effects on participants' health and organizational impact on the healthcare system]
2024     NIHR Health Technology Assessment programme Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis
2024     National Institute for Health and Care Excellence (NICE) Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. NICE technology appraisal guidance 1003
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery – Update of Commission V22-02]
2024     NIHR Health Technology Assessment programme Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
2024     National Institute for Health and Care Excellence (NICE) Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion. NICE technology appraisal guidance 1004
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for the early detection of familial hypercholesterolaemia in children and adolescents]
2024     NIHR Health and Social Care Delivery Program Relationship between staff and quality of care in care homes: StaRQ mixed methods study
2024     National Institute for Health and Care Excellence (NICE) Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 1005
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (malignant pleural mesothelioma - MPM)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures – Update for Commission N16-01]
2024     National Institute for Health and Care Excellence (NICE) Iptacopan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1000
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (renal cell carcinoma - RCC)]
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NICE technology appraisal guidance 1001
2024     Haute Autorite de sante (HAS) [Value of multiplex nucleic acid amplification tests (NAATs) in the medical management of lower respiratory tract infections]
2024     National Institute for Health and Care Excellence (NICE) Vibegron for treating symptoms of overactive bladder syndrome. NICE technology appraisal guidance 999
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Altuviiio lyophilized powder solution for IV injection]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-led delirium management and prevention
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 997
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Crysvita (XLH - x-linked hypophosphatemia)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarkers in primary breast cancer]
2024     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998